-
SAB Biotherapeutics to Present at Upcoming March Investor Conferences
March 4, 2021 03:30PM CENTRAL STANDARD TIME SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company…
-
SAB Biotherapeutics Announces New Appointments to its Board of Directors
December 16, 2020 06:00AM CENTRAL STANDARD TIME SIOUX, FALLS, SD--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a…
-
SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
November 30, 2020 07:45 AM EASTERN STANDARD TIME SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical…
-
SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19
Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients Second study initiated this month testing…
-
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19
First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological…
-
SAB Biotherapeutics Awarded $35.6M From U.S. Department Of Defense For COVID-19 And Scaling Rapid Response Antibody Program
Funds clinical development and manufacturing of SAB-185, a therapeutic candidate for COVID-19, as well as increased production capacity for rapid…
-
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza
July 30, 2020 08:48 AM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company…
-
SAB Biotherapeutics Closes Series B Funding
July 17, 2020 12:18 PM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company…
-
SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020
SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully…
-
SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate
SAB-185 is a human polyclonal antibody therapeutic that potently neutralizes live SARS-CoV-2 at titers 4X higher than convalescent plasma. Data suggests…
-
SAB Biotherapeutics Advances Therapeutic For COVID-19 In Partnership With Department Of Defense And BARDA
SAB’s novel approach generates targeted human antibodies without the need for human donors; on-track to have therapeutic candidate ready by summer 2020…
-
CSL Behring And SAB Biotherapeutics Join Forces To Deliver New Potential COVID-19 Therapeutic
April 08, 2020 at 8 a.m. ET COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2,…